{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:54:12Z","timestamp":1765828452282,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017228","name":"European Genomic Institute for Diabetes","doi-asserted-by":"publisher","award":["ANR-10-LABX-0046"],"award-info":[{"award-number":["ANR-10-LABX-0046"]}],"id":[{"id":"10.13039\/100017228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","award":["9987"],"award-info":[{"award-number":["9987"]}],"id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["FI19\/00153"],"award-info":[{"award-number":["FI19\/00153"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G015321N"],"award-info":[{"award-number":["G015321N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","award":["CPII20 \/00010"],"award-info":[{"award-number":["CPII20 \/00010"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/00062","PI21\/02045"],"award-info":[{"award-number":["PI22\/00062","PI21\/02045"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016386","name":"Government of Valencia Ministry of Innovation Universities Science and Society","doi-asserted-by":"publisher","award":["AICO\/2021\/081"],"award-info":[{"award-number":["AICO\/2021\/081"]}],"id":[{"id":"10.13039\/501100016386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108450","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:01:25Z","timestamp":1744131685000},"page":"108450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome"],"prefix":"10.1016","volume":"160","author":[{"given":"Carlos","family":"Villarroel-Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Solsona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khamis","family":"Zibar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Ayel\u00e9n","family":"Schiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Hennuyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorien","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo D.","family":"Enriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolien","family":"De Bosscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herminia","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Cabedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108450_bb0005","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bioorg.2025.108450_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0140-6736(09)61794-3","article-title":"The metabolic syndrome","volume":"375","author":"Eckel","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bioorg.2025.108450_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113535","article-title":"Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: an overview","volume":"221","author":"Villarroel-Vicente","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0020","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108450_bb0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1460-2075.1992.tb05072.x","article-title":"The mouse peroxisome proliferator activated receptor recognizes a response element in the 5\u2032 flanking sequence of the rat acyl CoA oxidase gene","volume":"11","author":"Tugwood","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2025.108450_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.108450_bb0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.108450_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2515\/therapie:2007051","article-title":"PPAR agonists and the metabolic syndrome","volume":"62","author":"Staels","year":"2007","journal-title":"Therapie"},{"key":"10.1016\/j.bioorg.2025.108450_bb0045","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator\u2013activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2025.108450_bb0050","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1210\/me.2013-1427","article-title":"Minireview: challenges and opportunities in development of PPAR agonists","volume":"28","author":"Wright","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdiacomp.2010.06.006","article-title":"Selective modulation of PPAR\u03b3 activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes","volume":"25","author":"Dunn","year":"2011","journal-title":"J. Diabetes Complicat."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108450_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108450_bb0065","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1021\/acs.jnatprod.9b00003","article-title":"Polycerasoidol, a natural prenylated benzopyran with a dual PPARalpha\/PPARgamma agonist activity and anti-inflammatory effect","volume":"82","author":"Bermejo","year":"2019","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2025.108450_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116532","article-title":"Synthesis and biological studies of \"Polycerasoidol\" and \"trans-delta-Tocotrienolic acid\" derivatives as PPARalpha and\/or PPARgamma agonists","volume":"53","author":"Vila","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0075","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1021\/acsmedchemlett.1c00400","article-title":"Synthesis of 2-prenylated alkoxylated benzopyrans by Horner-Wadsworth-Emmons olefination with PPARalpha\/gamma agonist activity","volume":"12","author":"Garcia","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108450_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115162","article-title":"Synthesis of benzopyran derivatives as PPARalpha and\/or PPARgamma activators","volume":"27","author":"Bermejo","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106638","article-title":"Anti-inflammatory effects and improved metabolic derangements in ob\/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity","volume":"187","author":"Marques","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108450_bb0090","doi-asserted-by":"crossref","first-page":"18594","DOI":"10.1039\/D2RA02896D","article-title":"Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs - a review","volume":"12","author":"Ajani","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108450_bb0095","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.chemrev.8b00567","article-title":"Progress in the chemistry of tetrahydroquinolines","volume":"119","author":"Muthukrishnan","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.108450_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115973","article-title":"A comprehensive review on the biological interest of quinoline and its derivatives","volume":"32","author":"Matada","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/943162","article-title":"A comprehensive review on metabolic syndrome","volume":"2014","author":"Kaur","year":"2014","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.bioorg.2025.108450_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129770","article-title":"Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects","volume":"106","author":"Villarroel-Vicente","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108450_bb0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jo026203i","article-title":"Highly regioselective Friedl\u00e4nder annulations with unmodified ketones employing novel amine catalysts: syntheses of 2-substituted quinolines, 1,8-naphthyridines, and related heterocycles","volume":"68","author":"Dormer","year":"2003","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1039\/B613775J","article-title":"A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes","volume":"5","author":"Li","year":"2007","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0125","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/0040-4020(95)00991-4","article-title":"Reduction of quinolines to 1,2,3,4-tetrahydro derivatives employing a combination of NaCNBH3 and BF3.OEt2","volume":"52","author":"Srikrishna","year":"1996","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.108450_bb0130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/jo00805a022","article-title":"Formic acid-formaldehyde methylation of amines","volume":"36","author":"Pine","year":"1971","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0135","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jmb.2013.05.010","article-title":"Molecular mechanism of peroxisome proliferator-activated receptor alpha activation by WY14643: a new mode of ligand recognition and receptor stabilization","volume":"425","author":"Bernardes","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/415813a","article-title":"Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha","volume":"415","author":"Xu","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108450_bb0145","first-page":"E2563","article-title":"Structural basis for specific ligation of the peroxisome proliferator-activated receptor delta","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.108450_bb0150","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/ci3006148","article-title":"Discovery of a novel selective PPARgamma ligand with partial agonist binding properties by integrated in silico\/in vitro work flow","volume":"53","author":"Kouskoumvekaki","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108450_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.phrs.2009.04.006","article-title":"The role of PPARs in modulating cardiac metabolism in diabetes","volume":"60","author":"Holness","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108450_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/bbrc.2001.5608","article-title":"Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha","volume":"287","author":"Wu","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108450_bb0165","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/bj20011841","article-title":"Evaluation of the role of peroxisome-proliferator-activated receptor alpha in the regulation of cardiac pyruvate dehydrogenase kinase 4 protein expression in response to starvation, high-fat feeding and hyperthyroidism","volume":"364","author":"Holness","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.108450_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","article-title":"The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus","volume":"109","author":"Finck","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108450_bb0175","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/db08-0477","article-title":"Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue","volume":"57","author":"Cadoudal","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2025.108450_bb0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1194\/jlr.M019182","article-title":"Regulation of skeletal muscle lipolysis and oxidative metabolism by the co-lipase CGI-58","volume":"53","author":"Badin","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bioorg.2025.108450_bb0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/13813455.2013.829105","article-title":"PPARdelta activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference","volume":"120","author":"Feng","year":"2014","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mito.2019.07.009","article-title":"Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation","volume":"49","author":"Pettersen","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.bioorg.2025.108450_bb0195","doi-asserted-by":"crossref","first-page":"10539","DOI":"10.1093\/nar\/gkw742","article-title":"Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPAR\u03b1","volume":"44","author":"Ratman","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108450_bb0200","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0960-894X(01)00188-3","article-title":"Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis","volume":"11","author":"Brown","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108450_bb0205","first-page":"1007","article-title":"PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation","volume":"2011","author":"Varga","year":"1812","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2025.108450_bb0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/CT:6:2:111","article-title":"The NF-kappaB regulatory network","volume":"6","author":"Brasier","year":"2006","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0215","doi-asserted-by":"crossref","first-page":"L622","DOI":"10.1152\/ajplung.00477.2005","article-title":"NF-kappa B activation as a pathological mechanism of septic shock and inflammation","volume":"290","author":"Liu","year":"2006","journal-title":"Am. J. Phys. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0220","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbalip.2007.04.021","article-title":"PPARalpha in atherosclerosis and inflammation","volume":"1771","author":"Zandbergen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2025.108450_bb0225","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108450_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/132960","article-title":"Peroxisome proliferator activated receptors and lipoprotein metabolism","volume":"2008","author":"Kersten","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108450_bb0235","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108450_bb0240","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1152\/ajpendo.90632.2008","article-title":"PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle","volume":"297","author":"Remels","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.108450_bb0245","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2353\/ajpath.2010.091010","article-title":"Peroxisome proliferator-activated receptor delta regulates inflammation via NF-kappaB signaling in polymicrobial sepsis","volume":"177","author":"Zingarelli","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0250","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bcp.2010.12.004","article-title":"The peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1","volume":"81","author":"Barroso","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/2230-8210.146874","article-title":"Assessment of insulin sensitivity\/resistance","volume":"19","author":"Gutch","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.108450_bb0260","doi-asserted-by":"crossref","first-page":"21128","DOI":"10.1016\/S0021-9258(17)45336-1","article-title":"Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines","volume":"265","author":"Mukaida","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0265","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1074\/jbc.273.6.3285","article-title":"Haegeman, p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor","volume":"273","author":"Vanden Berghe","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0270","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1039\/c2ob25593f","article-title":"Synthesis and evaluation of new polyenic compounds as potential PPARs modulators","volume":"10","author":"Amans","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2025.108450_bb0275","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0042-6822(73)90341-3","article-title":"A new technique for the assay of infectivity of human adenovirus 5 DNA","volume":"52","author":"Graham","year":"1973","journal-title":"Virology"},{"key":"10.1016\/j.bioorg.2025.108450_bb0280","first-page":"283","article-title":"Studies on the induction of the interleukin-6 promoter in cell lines of human and simian origin","volume":"5","author":"Vanhoenacker","year":"1994","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.bioorg.2025.108450_bb0285","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1073\/pnas.0806742106","article-title":"PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB","volume":"106","author":"Bougarne","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.108450_bb0290","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3389\/fimmu.2019.01769","article-title":"Mechanisms underlying the functional cooperation between PPARalpha and GRalpha to attenuate inflammatory responses","volume":"10","author":"Bougarne","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.108450_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-0733-5_3","article-title":"Selection of reliable reference genes for RT-qPCR analysis","volume":"1160","author":"Hellemans","year":"2014","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.bioorg.2025.108450_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100562","article-title":"Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation","volume":"9","author":"Zaafar","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108450_bb0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/JOE-15-0219","article-title":"Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis","volume":"227","author":"Andr\u00e9s-Blasco","year":"2015","journal-title":"J. Endocrinol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:26:37Z","timestamp":1762223197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682500330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"alternative-id":["S004520682500330X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108450","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108450"}}